Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥13,020 JPY
Change Today -10.00 / -0.08%
Volume 181.3K
4528 On Other Exchanges
Symbol
Exchange
Munich
Tokyo
OTC US
OTC US
As of 12:49 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

ono pharmaceutical co ltd (4528) Snapshot

Open
¥13,000
Previous Close
¥13,030
Day High
¥13,050
Day Low
¥12,830
52 Week High
03/9/15 - ¥14,550
52 Week Low
06/12/14 - ¥7,710
Market Cap
1.5T
Average Volume 10 Days
350.7K
EPS TTM
¥122.40
Shares Outstanding
117.8M
EX-Date
09/28/15
P/E TM
106.4x
Dividend
¥180.00
Dividend Yield
1.39%
Current Stock Chart for ONO PHARMACEUTICAL CO LTD (4528)

Related News

No related news articles were found.

ono pharmaceutical co ltd (4528) Related Businessweek News

No Related Businessweek News Found

ono pharmaceutical co ltd (4528) Details

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents in Japan and internationally. Its products primarily include Rivastach Patch to treat Alzheimer's disease; Glactiv and FORXIGA tablets for the treatment of type II diabetes; Emend capsules/Proemend Intravenous injection for chemotherapy-induced nausea and vomiting; Recalbon tablets to treat osteoporosis; Staybla tablets for the treatment of overactive bladder; Opalmon tablets for peripheral circulatory disorder; and Onon capsules for the treatment of bronchial asthma and allergic rhinitis. The company’s products also comprise Onon dry syrup for the treatment of bronchial asthma and allergic rhinitis; Kinedak tablets for the treatment of diabetic peripheral neuropathy; Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis; Elaspol injection for the treatment of acute lung injury associated with systemic inflammatory response syndrome; Onoact injection for the treatment of tachyarrhythmia; and ORENCIA injection for the treatment of rheumatoid arthritis. In addition, it is involved in developing drugs for various indications, such as melanoma, renal cell carcinoma, non-small cell lung cancer, bronchial asthma, allergic rhinitis, irritable bowel syndrome, glaucoma, ocular hypertension, B-cell lymphoma, underactive bladder, gastroesophageal reflux disease, Parkinson’s disease, portal hypertension, acute heart failure, head and neck carcinoma, glioblastoma, diffuse large b cell lymphoma, follicular lymphoma, chronic myeloid leukemia, and juvenile idiopathic arthritis, as well as esophageal, ovarian, and colon cancer. Ono Pharmaceutical Co., Ltd. has drug discovery strategic alliances with Array BioPharma Inc.; Locus Pharmaceuticals, Inc.; BioSeek LLC; Receptos Inc.; Xention Limited; BioFocus DPI Limited; Evotec AG; Scil Proteins GmbH; and Domain Therapeutics S.A. The company was founded in 1717 and is headquartered in Osaka, Japan.

Founded in 1717

ono pharmaceutical co ltd (4528) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ono pharmaceutical co ltd (4528) Key Developments

Ono Pharmaceutical Co., Ltd. Announces Unaudited Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2015 and for the Year Ending March 31, 2016

Ono Pharmaceutical Co., Ltd. announced unaudited consolidated earnings results for the year ended March 31, 2015. For the year, the company reported revenue of JPY 135,775 million compared to JPY 143,247 million a year ago. Operating profit was JPY 14,794 million compared to JPY 26,429 million a year ago. Profit before tax was JPY 18,305 million compared to JPY 29,464 million a year ago. Profit for the year was JPY 13,216 million compared to JPY 20,541 million a year ago. Profit for the year attributable to owners of the parent company was JPY 12,976 million compared to JPY 20,344 million a year ago. Basic earnings per share were JPY 122.40 compared to JPY 191.90 a year ago. Net cash provided by operating activities was JPY 31,579 million compared to JPY 28,422 million a year ago. Purchase of property, plant and equipment was JPY 17,540 million compared to JPY 5,816 million a year ago. Purchase of intangible assets was JPY 13,578 million compared to JPY 7,041 million a year ago. The company provided consolidated earnings guidance for the six months ending September 30, 2015. The company expects revenue of JPY 64,100 million, operating profit of JPY 7,500 million, profit before tax of JPY 8,800 million, profit (owners of the parent company) of JPY 6,200 million, basic earnings per share of JPY 58.49. The company provided consolidated earnings guidance for the year ending March 31, 2016. The company expects revenue of JPY 135,100 million, operating profit of JPY 14,000 million, profit before tax of JPY 16,500 million, profit (owners of the parent company) of JPY 11,600 million, basic earnings per share of JPY 109.43.

Ono Pharmaceutical Co., Ltd., 2015 Earnings Call, May 13, 2015

Ono Pharmaceutical Co., Ltd., 2015 Earnings Call, May 13, 2015

Ono Pharmaceutical and China Chemical & Pharmaceutical Sign Agreement to Develop and Commercialize Limaprost in Taiwan

Ono Pharmaceutical and China Chemical & Pharmaceutical signed an agreement on the development and commercialization of Ono's Limaprost in Taiwan. Under the agreement, Ono will give CCPC exclusive rights to develop and commercialize Limaprost for the treatment of lumbar spinal canal stenosis in Taiwan, after obtaining marketing authorization. CCPC will pay sales royalties to Ono following Limaprost's launch in Taiwan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4528:JP ¥13,020.00 JPY -10.00

4528 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €18.37 EUR +0.05
Ironwood Pharmaceuticals Inc $13.74 USD -0.095
Nektar Therapeutics $11.53 USD -0.34
Santen Pharmaceutical Co Ltd ¥1,799 JPY -32.00
Synergy Health PLC 2,164 GBp -104.00
View Industry Companies
 

Industry Analysis

4528

Industry Average

Valuation 4528 Industry Range
Price/Earnings 100.0x
Price/Sales 10.1x
Price/Book 2.9x
Price/Cash Flow 117.0x
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONO PHARMACEUTICAL CO LTD, please visit www.ono.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.